国际肿瘤学杂志 ›› 2011, Vol. 38 ›› Issue (8): 569-571.

• 综述 • 上一篇    下一篇

SIRT1与肿瘤

郭淑芹, 朱春英, 张云良   

  1. 保定市第一中心医院
  • 收稿日期:2011-04-13 修回日期:2011-07-03 出版日期:2011-08-08 发布日期:2011-08-29
  • 通讯作者: 朱春英 E-mail:330285349@qq.com

SIRT1 and neoplasms.

GUO  Shu-Qin, ZHU  Chun-Ying, ZHANG  Yun-Liang   

  • Received:2011-04-13 Revised:2011-07-03 Online:2011-08-08 Published:2011-08-29

摘要: SIRT1(Sirtuin type 1)是一种依赖于烟酰胺腺嘌呤二核苷酸(NAD+)的组蛋白脱乙酰酶,参与组蛋白的共价修饰,并可通过转录、翻译及翻译后修饰等多种途径参与肿瘤的发生发展过程,因此肿瘤细胞内SIRT1的表达或功能异常是肿瘤发生发展的重要机制之一,并可能成为治疗肿瘤的新的潜在靶点。

关键词: SIRT1, 肿瘤, 靶向治疗

Abstract: SIRT1 (Sirtuin type 1) is dependent on nicotinamide adenine dinucleotide (NAD +) group Protein deacetylase involved in the covalent modification of histones, participated in tumor development and progression through transcription, translation and post-translational modification and so on. Therefore, the expression of SIRT1 in tumor cells or abnormal function could be one of the important mechanisms of tumor development,and may become a new potential therapeutic targets for cancer

Key words: SIRT1, neoplasms, Target therapy